Hybrid intelligent system for disease diagnosis based on artificial neural networks, fuzzy logic, and genetic algorithms

Disease diagnosis often involves acquiring medical images using devices such as MRI, CT scan, x-ray, or mammograms of patients' organs. Though many medical diagnostic applications have been proposed; finding subtle cancerous cells is still an issue because they are very difficult to be identified. This paper presents an architecture that utilizes a learning algorithm, and uses soft computing to build a medical knowledge base and an inference engine for classifying new images. This system is built on the strength of artificial neural networks, fuzzy logic, and genetic algorithms. These machine intelligence are combined in a complementary approach to overcome the weakness of each other. Moreover, the system also uses Wavelet Transform and Principal Component Analysis for pre-processing and feature to produce features to be used as input to the learning algorithm. 2011 Springer-Verlag.Scopu

Computer aided diagnosis system based on machine learning techniques for lung cancer

Cancer is a leading cause of death worldwide. Lung cancer is a type of cancer that is considered as one of the most leading causes of death globally. In Malaysia, it is the 3rd common cancer type and the 2nd type of cancer among men. In this paper, machine learning techniques have been utilized to develop a computer-aided diagnosis system for lung cancer. The system consists of feature extraction phase, feature selection phase and classification phase. For feature extraction/selection, different wavelets functions have been applied in order to find the one that produced the highest accuracy. Clustering-K-nearest-neighbor algorithm has been developed/utilized for classification. Japanese Society of Radiological Technology's standard dataset of lung cancer has been used to test the system. The data set has 154 nodule regions (abnormal) and 92 non-nodule regions (normal). Accuracy levels of over 96% for classification have been achieved which demonstrate the merits of the proposed approach. 2012 IEEE.Scopu

A scoping review of artificial intelligence-based methods for diabetes risk prediction

Abstract The increasing prevalence of type 2 diabetes mellitus (T2DM) and its associated health complications highlight the need to develop predictive models for early diagnosis and intervention. While many artificial intelligence (AI) models for T2DM risk prediction have emerged, a comprehensive review of their advancements and challenges is currently lacking. This scoping review maps out the existing literature on AI-based models for T2DM prediction, adhering to the PRISMA extension for Scoping Reviews guidelines. A systematic search of longitudinal studies was conducted across four databases, including PubMed, Scopus, IEEE-Xplore, and Google Scholar. Forty studies that met our inclusion criteria were reviewed. Classical machine learning (ML) models dominated these studies, with electronic health records (EHR) being the predominant data modality, followed by multi-omics, while medical imaging was the least utilized. Most studies employed unimodal AI models, with only ten adopting multimodal approaches. Both unimodal and multimodal models showed promising results, with the latter being superior. Almost all studies performed internal validation, but only five conducted external validation. Most studies utilized the area under the curve (AUC) for discrimination measures. Notably, only five studies provided insights into the calibration of their models. Half of the studies used interpretability methods to identify key risk predictors revealed by their models. Although a minority highlighted novel risk predictors, the majority reported commonly known ones. Our review provides valuable insights into the current state and limitations of AI-based models for T2DM prediction and highlights the challenges associated with their development and clinical integration

Cardiovascular Disease Diagnosis from DXA Scan and Retinal Images Using Deep Learning

Cardiovascular diseases (CVD) are the leading cause of death worldwide. People affected by CVDs may go undiagnosed until the occurrence of a serious heart failure event such as stroke, heart attack, and myocardial infraction. In Qatar, there is a lack of studies focusing on CVD diagnosis based on non-invasive methods such as retinal image or dual-energy X-ray absorptiometry (DXA). In this study, we aimed at diagnosing CVD using a novel approach integrating information from retinal images and DXA data. We considered an adult Qatari cohort of 500 participants from Qatar Biobank (QBB) with an equal number of participants from the CVD and the control groups. We designed a case-control study with a novel multi-modal (combining data from multiple modalities—DXA and retinal images)—to propose a deep learning (DL)-based technique to distinguish the CVD group from the control group. Uni-modal models based on retinal images and DXA data achieved 75.6% and 77.4% accuracy, respectively. The multi-modal model showed an improved accuracy of 78.3% in classifying CVD group and the control group. We used gradient class activation map (GradCAM) to highlight the areas of interest in the retinal images that influenced the decisions of the proposed DL model most. It was observed that the model focused mostly on the centre of the retinal images where signs of CVD such as hemorrhages were present. This indicates that our model can identify and make use of certain prognosis markers for hypertension and ischemic heart disease. From DXA data, we found higher values for bone mineral density, fat content, muscle mass and bone area across majority of the body parts in CVD group compared to the control group indicating better bone health in the Qatari CVD cohort. This seminal method based on DXA scans and retinal images demonstrate major potentials for the early detection of CVD in a fast and relatively non-invasive manner

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events